- Home
- WULF vs RYTM Comparison
WULF vs RYTM Comparison
Compare WULF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WULF | RYTM |
|---|---|---|
| Founded | 1952 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.4B |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WULF | RYTM |
|---|---|---|
| Price | $16.08 | $87.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $18.54 | ★ $131.21 |
| AVG Volume (30 Days) | ★ 23.8M | 704.9K |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $168,455,000.00 | N/A |
| Revenue This Year | $128.43 | $57.46 |
| Revenue Next Year | $181.70 | $85.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $2.06 | $45.91 |
| 52 Week High | $18.51 | $122.20 |
Technical Indicators
Market Signals| Indicator | WULF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 39.43 |
| Support Level | $11.30 | $85.59 |
| Resistance Level | $16.76 | $96.26 |
| Average True Range (ATR) | 1.15 | 5.08 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 56.47 | 25.76 |
Price Performance
Historical ComparisonAbout WULF TeraWulf Inc.
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.